Deckers Outdoor Corp. 10-Q Summary (Period Ended Sept 30, 2002)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Deckers Outdoor Corporation for the three and nine-month periods ended September 30, 2002. The company operates three strategic business units: Teva, Simple, and Ugg. The reporting period includes the implementation of new accounting standards (SFAS 142) and significant litigation developments.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2002 | Nine Months Ended Sept 30, 2002 |
|---|---|---|
| Net Sales | $17.73 million | $73.36 million |
| Gross Profit | $6.70 million (37.8% margin) | $31.88 million (43.5% margin) |
| Net Loss | $(2.55) million | $(8.72) million |
| Net Loss Per Share (Diluted) | $(0.27) | $(0.90) |
| Cash and Equivalents | $20.49 million (as of Sept 30, 2002) | |
| Working Capital | $44.77 million | |
| Operating Cash Flow (9 months) | $4.67 million | |
| Total Debt | $197,000 (Notes payable + Long-term debt) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 26.4% year-over-year for the quarter and 4.0% for the nine-month period. Ugg sales drove significant growth (up 47.3% in Q3), while Simple sales declined 19.9% in Q3 due to international market difficulties.
- Profitability Impact: Despite sales growth, the company reported a net loss. The nine-month net loss of $8.72 million was primarily driven by a non-cash goodwill impairment charge of $8.97 million resulting from the adoption of SFAS 142.
- Operating Income: Excluding the accounting change, the company generated operating income of $509,000 for the nine months, compared to $1.83 million in the prior year. This decline was due to increased litigation costs and SG&A expenses.
- Litigation Costs: Special litigation charges increased to $3.52 million in Q3 2002 from $2.18 million in Q3 2001, related to a Montana lawsuit.
Guidance, Outlook, and Risks
- Acquisition: On October 10, 2002, the company signed a definitive agreement to acquire the Teva brand assets for approximately $62 million (cash and stock). The deal is expected to close before year-end and is projected to be accretive to earnings by $1 million in 2003.
- 2002 Guidance: Management expects full-year 2002 net sales to range from $95 million to $96 million. Diluted EPS is expected to range from a loss of $0.83 to $0.84 (including the SFAS 142 charge) or $0.09 to $0.10 (excluding the charge).
- 2003 Outlook: Projected net sales of $100 million to $105 million with diluted EPS of $0.38 to $0.43.
- Risks:
- Litigation: A federal judge ruled the company must pay an additional $4.29 million in the Montana case; settlement negotiations are ongoing.
- Trade: Potential exposure to European antidumping duties on footwear imported from China/Indonesia; a $500,000 reserve has been established.
- Seasonality/Weather: Sales are highly sensitive to weather conditions (cool springs hurt Teva; warm winters hurt Ugg).
- Supply Chain: Potential disruptions from West Coast port labor disputes.
Investor Verification Checklist
- Verify the status of the $4.29 million Montana litigation accrual and potential settlement terms.
- Confirm the closing of the $62 million Teva acquisition and the final terms of the $14 million senior subordinated notes financing.
- Monitor the impact of European antidumping duties on Teva sales margins and sourcing strategies.
- Review the performance of the Ugg brand in the upcoming fourth quarter, which is historically the strongest season for that line.
- Assess the effectiveness of the new ERP system implementation on SG&A expenses and inventory management.